explore -WSS

explore

author：comprehensive 2025-09-28 02:28:02 - browse：1765

Chris O'Meara/AP

Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers.

Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations. Those overpayments, the lawsuit alleges, ultimately come out of workers’ paychecks in the form of high health insurance premiums, higher out-of-pocket drug costs, and stunted wage growth.

In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a generic medicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： WHO recommends dropping component of many flu vaccines

entertainment

WSS

WHO recommends dropping component of many flu vaccines

WHO recommends dropping component of many flu vaccines

The future of health care in the House

Physician executives need more than on

Intercept Pharmaceuticals sells itself for less than $1 billion

The future of health care in the House

hotspot

explore

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Medicare proposal to cover medical devices draws a mixed reaction

Health tech startups drop sharply from 2021 highs

Anesthesiologist group: stop taking Ozempic before surgery

Mindstrong's demise and the future of mental health care

As demand for Covid shots wanes, Moderna seeks its next success

Inequities make cancer less preventable for women: report

Affirmative action in medical school literally saved lives

After a drawn out lobbying fight, ARPA

entertainment

FDA rejects Alnylam's heart disease treatment over insufficient data

Chemotherapy drug shortage eases slightly but still widespread

Intercept Pharmaceuticals sells itself for less than $1 billion

Menendez indictment could see pharma lose a key ally

FDA advisers vote against ALS treatment from BrainStorm

Address the ethical violations that led to 'Three Identical Strangers'

hotspot

hotspot

entertainment

explore